Show simple item record

dc.contributor.authorStoker, Thomas
dc.contributor.authorBarker, Roger
dc.date.accessioned2018-09-20T12:06:45Z
dc.date.available2018-09-20T12:06:45Z
dc.date.issued2018-08
dc.identifier.issn1173-8804
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/280538
dc.description.abstractParkinson's disease is the second most common neurodegenerative disorder. It is characterised by a typical movement disorder that occurs in part because of the selective degeneration of the dopaminergic neurons of the substantia nigra pars compacta. Current treatment for the motor disorder of Parkinson's disease consists of dopaminergic medications, but these come with significant adverse effects, themselves an important part of the clinical course of Parkinson's disease, particularly in advanced stages. Therefore, treatment is needed that can restore dopaminergic tone in the striatum in a physiological and targeted manner to avert these side effects. A number of potential regenerative treatments have been developed with a view to achieving this. Following decades of optimisation and development of stem-cell-based treatments and viral gene delivery, clinical trials are on the horizon. For these treatments to be widely useful, they must be clinically effective, cost efficient and safe, and a number of practical aspects regarding storage and delivery of treatment must be optimised. Many barriers have been overcome, and the field of regenerative medicine for Parkinson's disease is now increasingly focussed on how these treatments will be delivered, demonstrating the significant progress that has been made and the optimism surrounding these approaches.
dc.description.sponsorshipThe authors acknowledge financial support from the following organisations: Medical Research Council, Wellcome Trust Stem Cell Institute (Cambridge), National Institute for Health Research Biomedical Research Centre, and the Cure Parkinson’s Trust
dc.format.mediumPrint
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.subjectHumans
dc.subjectParkinson Disease
dc.subjectDopamine
dc.subjectStem Cell Transplantation
dc.subjectRegenerative Medicine
dc.subjectGenetic Vectors
dc.subjectPatient Selection
dc.subjectClinical Trials as Topic
dc.subjectGenetic Therapy
dc.titleRegenerative Therapies for Parkinson's Disease: An Update.
dc.typeArticle
prism.endingPage366
prism.issueIdentifier4
prism.publicationDate2018
prism.publicationNameBioDrugs
prism.startingPage357
prism.volume32
dc.identifier.doi10.17863/CAM.27907
dcterms.dateAccepted2018-07-09
rioxxterms.versionofrecord10.1007/s40259-018-0294-1
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-08
dc.contributor.orcidStoker, Thomas [0000-0001-5186-7630]
dc.contributor.orcidBarker, Roger [0000-0001-8843-7730]
dc.identifier.eissn1179-190X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idMedical Research Council (MC_PC_12009)
cam.issuedOnline2018-07-19
rioxxterms.freetoread.startdate2019-07-19


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record